Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind’s clinical trial at Yale and Johns Hopkins